Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Prospective Cohort Study to Assess Clinical Effectiveness of an Investigational Digital Therapeutic (CT-155) in Patients With Experiential Negative Symptoms of Schizophrenia
NCT06791122 · View on ClinicalTrials.gov ↗
Study Summary
This study is open to people aged 18 years or older with schizophrenia. People can join the study if they are willing to use a smartphone app called CT-155. This app is being developed to help people with schizophrenia manage their negative symptoms. The purpose of this study is to gather new information on CT-155. Researchers want to see how well it works, how well participants use the study app, and how it affects the use of health care services. Participants use the app for 16 weeks. They may continue using it for another 16 weeks. During the study, participants continue with their normal treatment for schizophrenia. Participants are in the study for about a year. During this time, they visit the study site every 2 months. During this study, doctors regularly check participants' schizophrenia symptoms and overall quality of life. Researchers may also compare the healthcare data of study participants with a similar group of people with schizophrenia who are not part of the study. The doctors also regularly check participants' health and take note of any unwanted effects.
Conditions Studied
Interventions
- DEVICE Digital therapeutic (CT-155)
Study Locations (20)
California
- Sun Valley Behavioral Med Center — Imperial
- University of California San Diego — La Jolla
- North Country Clinical Research Inc — Oceanside
- ATP Clinical Research, Inc. — Orange
- NRC Research Institute — Orange
- Stanford University Medical Center — Stanford
- Collaborative Neuroscience Research — Torrance
Florida
- Galiz Research — Hialeah
- New Life Medical Research Center, Inc. — Hialeah
- University of Miami — Miami
- Global Life Research Network — Miami
- Interventional Psychiatry of Tampa Bay — Tampa
- Health Synergy Clinical Research, LLC — West Palm Beach
Maryland
- Sheppard Pratt Physicians's Practice Association, Inc. — Baltimore
- Center for Behavioral Health, LLC — Gaithersburg
Massachusetts
- Boston Neurobehavioral Associates — Brookline
- University of Massachusetts - Worcester — Worcester
Connecticut
- CT Clinical Research — Cromwell
Georgia
- Emory University — Atlanta
Michigan
- Western Michigan University — Kalamazoo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 262 participants |
| Start Date | 2025-01-23 |
| Est. Completion | 2026-08-26 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06791122
The ClinicalTrials.gov registry entry for NCT06791122 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 262 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 203 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention — of which Digital therapeutic (CT-155) is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06791122 reports 20 study locations spanning 7 distinct geographic areas — top geographies include California, Florida, Maryland. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06791122 about?
NCT06791122 is a clinical study titled "A Prospective Cohort Study to Assess Clinical Effectiveness of an Investigational Digital Therapeutic (CT-155) in Patients With Experiential Negative Symptoms of Schizophrenia". This study is open to people aged 18 years or older with schizophrenia. People can join the study if they are willing to use a smartphone app called CT-155. This app is being developed to help people with schizophrenia manage their negative symptoms. The purpose of this study is to gather new infor...
What is the current status of trial NCT06791122?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 262 participants. The study started on 2025-01-23. Estimated completion is 2026-08-26.
What conditions does trial NCT06791122 study?
This clinical trial studies the following conditions: Schizophrenia. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06791122?
The interventions under investigation include: Digital therapeutic (CT-155) (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06791122?
This trial is sponsored by Boehringer Ingelheim, which has 203 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06791122 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Georgia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.